Sofinnova Investments’s Blueprint Medicines BPMC Stock Holding History

Sofinnova Investments’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-261,039	Closed	-$23.1M	–	67
2025 Q1	$23.1M	Buy	+261,039	New	+$25.5M	1.51%	22
2022 Q1	–	Sell	-245,182	Closed	-$26.3M	–	68
2021 Q4	$26.3M	Buy	245,182 +63,322	+35%	+$6.62M	1.53%	17
2021 Q3	$18.7M	Buy	+181,860	New	+$16.9M	1.11%	18
2020 Q3	–	Sell	-94,891	Closed	-$7.4M	–	74
2020 Q2	$7.4M	Buy	94,891 +31,791	+50%	+$2.15M	0.47%	43
2020 Q1	$3.69M	Buy	+63,100	New	+$4.06M	0.34%	39
2019 Q2	–	Sell	-71,866	Closed	-$5.75M	–	74
2019 Q1	$5.75M	Buy	+71,866	New	+$5.31M	0.55%	34
2018 Q4	–	Sell	-51,339	Closed	-$4.01M	–	62
2018 Q3	$4.01M	Sell	51,339 -40,861	-44%	-$2.84M	0.36%	42
2018 Q2	$5.85M	Buy	+92,200	New	+$7.34M	0.66%	31

Other funds holding BPMC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Sofinnova Investments's BPMC Position: Q2 2025 in Review

Sofinnova Investments sold out of Blueprint Medicines (BPMC) in Q2 2025, closing a stake of 261,039 shares — an estimated $23.1M sold.

Sofinnova Investments first reported a position in BPMC in Q2 2018 and held it in 8 quarters. The position peaked at $26.3M in Q4 2021. 354 funds tracked by Wall St. Rank hold BPMC as of Q2 2025.

Sofinnova Investments reported no remaining Blueprint Medicines position as of Q2 2025 after selling out during the quarter.
Sofinnova Investments sold 261,039 Blueprint Medicines shares in Q2 2025, an estimated $23.1M.
Sofinnova Investments first reported a position in Blueprint Medicines in Q2 2018 and held it in 8 quarters.
Sofinnova Investments's Blueprint Medicines position peaked at $26.3M in Q4 2021.
354 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2025.

Based on Sofinnova Investments's 13F filing for Q2 2025, filed 14 Aug 2025.